← All organizations
Highest phase reached
Phase 4
First clinical trial
Feb 1, 2013First marketed drug
Dec 17, 2021First NDA
Dec 17, 2021Last known activity
Dec 31, 2025
Timeline
2000s
- Jun 1, 2009
argenx— Founded
2020s
- Dec 17, 2021
efgartigimod— Marketing Organization
- Dec 17, 2021
efgartigimod— NDA Secondary Org
- Dec 17, 2021
efgartigimod— NDA Organization
Drugs by trial phase (13 distinct, 77 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (3 own, 0 via acquisition)
Phase 2 (3 own, 0 via acquisition)
Phase 1 (6 own, 0 via acquisition)
Indications
Studied for
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Muscle Weakness
- Myasthenia Gravis
- Myelodysplastic Syndromes
- Nasopharyngeal Carcinoma
- Neoplasms
- Paresis
- Pemphigus
- Polyneuropathies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Preleukemia
- Purpura, Thrombocytopenic, Idiopathic
- Syndrome
- Thrombocytopenia
Marketed drugs (2)
Recent trials (50)
- NCT04777734Lead sponsorN/A—
- NCT07284420Lead sponsorPhase 2Dec 31, 2025
- NCT07287982Lead sponsorPhase 2Dec 19, 2025
- NCT07194850Lead sponsorPhase 2/Phase 3Oct 20, 2025
- NCT07091630Lead sponsorPhase 3Sep 16, 2025
- NCT06920004Lead sponsorPhase 3Aug 22, 2025
- NCT07011589CollaboratorPhase 1/Phase 2Jul 31, 2025
- NCT06909214Lead sponsorPhase 4Apr 17, 2025
- NCT06968338Lead sponsorPhase 1Apr 11, 2025
- NCT06860633CollaboratorPhase 4Mar 15, 2025
- NCT06765161CollaboratorPhase 3Feb 6, 2025
- NCT06799416Lead sponsorPhase 1Jan 14, 2025
- NCT06742190Lead sponsorPhase 3Dec 31, 2024
- NCT06684847Lead sponsorPhase 3Dec 31, 2024
- NCT06637072Lead sponsorPhase 4Nov 30, 2024
Details
- Founded
- Breda, NL Jun 1, 2009
- First NDA
- Dec 17, 2021
- Last known activity
- Dec 31, 2025
Designations held
- Orphan drug
- Fast track
Notes
--- Pre-folding founded info: 2018-06-01 Ghent None Belgium https://www.argenx.com/ ---